CTNNB1 Syndrome Natural History Study
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study follows people with CTNNB1 syndrome over time to better understand the condition. It does not test any new treatment—just collects information to help future research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have a doctor-confirmed diagnosis of CTNNB1 syndrome (genetic test and symptoms).
- You or your child can be any age from birth to 99 years old.
- A parent or legal guardian must be able to give permission (written or online) for the study.
- You or your child cannot be currently participating in a clinical trial for a treatment for CTNNB1 syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene replacement therapy given into the fluid around the brain to help children with CTNNB1 neurodevelopmental syndrome. The goal is to see if replacing the faulty gene can improve development and reduce symptoms.
This study follows people with a rare genetic muscle condition called TNNT1 myopathy over time. Researchers will track how the disease progresses to better understand it and help plan future treatments.
This study looks at MYT1L syndrome, a rare genetic condition that affects brain development. It aims to understand the disorder better by studying people with the syndrome and a comparison group.
This study looks at how Charcot-Marie-Tooth disease (CMT) or related inherited nerve conditions change over time. It may help researchers better understand what to expect and guide future treatments.
This study looks at people with CLN3 and other related forms of NCL (a childhood brain-wasting illness) to better describe symptoms and disease changes over time. You may be followed with regular check-ins, medical records, and sometimes NIH visits or sample collection.
This study looks at measurements and child-focused outcomes in babies and toddlers with myotonic dystrophy type 1 (DM1) that started in the newborn period. It may help researchers better track how the condition affects children and evaluate care plans more accurately.
Hear when a new CTNNB1 Neurodevelopmental Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.